Kenneth C Cassidy
Overview
Explore the profile of Kenneth C Cassidy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Martin J, Czeskis B, Urva S, Cassidy K
Eur J Pharm Sci
. 2024 Sep;
202:106895.
PMID: 39243911
Tirzepatide is a once-weekly GIP/GLP-1 receptor agonist used for treatment of type 2 diabetes (T2D) in adults and was recently approved for treatment of obesity. To determine the absorption, distribution,...
2.
Cuyckens F, Hvenegaard M, Cassidy K, Spracklin D, James A, Pedersen M, et al.
Drug Metab Dispos
. 2024 Jan;
52(3):153-158.
PMID: 38216306
The administration of radiolabeled drug candidates is considered the gold standard in absorption, distribution, metabolism, and excretion studies for small-molecule drugs since it allows facile and accurate quantification of parent...
3.
Young G, Spracklin D, James A, Hvenegaard M, Pedersen M, Wagner D, et al.
Clin Pharmacol Ther
. 2023 Nov;
115(5):931-938.
PMID: 38018358
A review of the use of microdoses and isotopic microtracers for clinical intravenous pharmacokinetic (i.v. PK) data provision is presented. The extent of application of the varied approaches available and...
4.
Young G, Spracklin D, James A, Hvenegaard M, Scarfe G, Wagner D, et al.
Clin Pharmacol Ther
. 2022 Jun;
113(4):775-781.
PMID: 35733280
The human absorption, distribution, metabolism, and excretion (hADME) study is the cornerstone of the clinical pharmacology package for small molecule drugs, providing comprehensive information on the rates and routes of...
5.
Wickremsinhe E, Hynes S, Payne C, Guo Y, Cassidy K
Xenobiotica
. 2019 Dec;
50(7):793-804.
PMID: 31847673
The disposition and metabolism of prexasertib, a CHK-1 inhibitor was characterised over a 120 h period following a single 170-mg intravenous dose of [C]prexasertib (50 µCi) to 6 patients with...
6.
Zhou X, Cassidy K, Hudson L, Mohutsky M, Sawada G, Hao J
Pharmacol Res Perspect
. 2019 Jul;
7(4):e00502.
PMID: 31333846
The enterohepatic circulation (EHC) of drugs is often the result of the direct glucuronidation, excretion of the metabolite into bile, followed by hydrolysis to the aglycone by the gut microbiome...
7.
Norman B, Fisher M, Schiffler M, Kuklish S, Hughes N, Czeskis B, et al.
J Med Chem
. 2018 Feb;
61(5):2041-2051.
PMID: 29425457
Two 2-aminoimidazole-based inhibitors, LY3031207 (1) and LY3023703 (2), of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme were found to cause drug-induced liver injury (DILI) in humans. We studied imidazole ring...
8.
Cassidy K, Yi P
Xenobiotica
. 2017 Nov;
48(12):1192-1205.
PMID: 29143555
1. This study assessed the value of a static in vitro human hepatocyte-murine stromal cell co-culture model to qualitatively and quantitatively predict human in vivo metabolic clearance pathways using C-labeled...
9.
Cassidy K, Gueorguieva I, Miles C, Rehmel J, Yi P, Ehlhardt W
Xenobiotica
. 2017 Apr;
48(4):382-399.
PMID: 28436712
1. The disposition and metabolism of galunisertib (LY2157299 monohydrate, a TGF-βRI Kinase/ALK5 Inhibitor) was characterized following a single oral dose of 150 mg of [C]-galunisertib (100 µCi) to six healthy...
10.
Zhou X, Rougee L, Bedwell D, Cramer J, Mohutsky M, Calvert N, et al.
Drug Metab Dispos
. 2016 May;
44(8):1184-92.
PMID: 27217490
The Zucker diabetic fatty (ZDF) rat, an inbred strain of obese Zucker fatty rat, develops early onset of insulin resistance and displays hyperglycemia and hyperlipidemia. The phenotypic changes resemble human...